Table 2.
Venetoclax-based regimens in patients with Philadelphia chromosome-positive (Ph+) AML and CML myeloid blast phase (MBP)
Regimen | Ph+ AML (n=7) | CML MBP (n=9) |
---|---|---|
Decitabine-based | 4 (57) | 5 (56) |
Intensive chemotherapy-based | 3 (43) | 4 (44) |
BCR-ABL TKI | ||
Ponatinib | 6 (86) | 4 (44) |
Dasatinib | 1 (14) | 3 (33) |
Bosutinib | 0 (0) | 1 (11) |
Nilotinib | 0 (0) | 1 (11) |
Results expressed as n (%) |